Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. - Wikidata - wikimedia - TriplyDB

Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

http://www.wikidata.org/entity/Q33437576

about

The role of water in activation mechanism of human N-formyl peptide receptor 1 (FPR1) based on molecular dynamics simulations Horizons in therapy for corneal angiogenesis.Roles of resolvins in the resolution of acute inflammation The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?Fish oil metabolites: translating promising findings from bench to bedside to reduce cardiovascular disease Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury.Specialized pro-resolving lipid mediators in the inflammatory response: An update Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?The influence of Cox-2 and bioactive lipids on hematological cancers.Significance of lipid mediators in corneal injury and repair.Resolution of Cochlear Inflammation: Novel Target for Preventing or Ameliorating Drug-, Noise- and Age-related Hearing Loss.Resolution, the grail for healthy ocular inflammation.Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model.The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation Effect of 15-lipoxygenase metabolites on angiogenesis: 15(S)-HPETE is angiostatic and 15(S)-HETE is angiogenic.Resolvins: natural agonists for resolution of pulmonary inflammation.Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.Macrophage depletion impairs corneal wound healing after autologous transplantation in mice Novel anti-inflammatory--pro-resolving mediators and their receptors Aspirin-triggered lipoxin A4 (15-epi-LXA4) increases the endothelial viability of human corneas storage in Optisol-GS.Resolvins and protectins in inflammation resolution.Inhibition of Corneal Inflammation by the Resolvin E1.Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats.Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs.Active Pedicle Epithelial Flap Transposition Combined with Amniotic Membrane Transplantation for Treatment of Nonhealing Corneal Ulcers Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation Resolvin D1 mitigates energy metabolism disorder after ischemia-reperfusion of the rat lung.Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion.Anti-inflammatory Agents: Present and Future Resolvin D1 reverts lipopolysaccharide-induced TJ proteins disruption and the increase of cellular permeability by regulating IκBα signaling in human vascular endothelial cells.Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1 Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology.Essential fatty acids and their metabolites as modulators of stem cell biology with reference to inflammation, cancer, and metastasis.The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis.New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration.

P2860

Q27315037-4FF7D0C2-5081-4A7D-8E1B-D2998A7BEB10 Q27691454-251BDBE5-B339-452A-8DDE-E0BAD2E1F2FA Q28244502-8B6912B7-1208-44EB-926C-4D638EF10920 Q28251512-7AC1F6C6-434C-4B4E-8F25-F2E5EE4707A9 Q28385429-8369E632-39D6-406B-9EFC-1D11F63C15B3 Q28716294-12151C69-D065-45AA-B85C-63F53928A628 Q30514238-E7EBF4BD-8E34-49FE-AB06-B21029785014 Q33556241-76AA2565-5CAF-40CB-B270-5758186C10A7 Q33657562-4C1193CF-E65F-4F8C-A804-7D2778FA659F Q33683210-F0A7FC8D-B86E-4CE0-8817-292E0DB925DE Q33688673-BF7EE5A3-AB3B-4C04-BBAD-075E9E8D3CD2 Q33784586-E499BDC2-99A1-4A3F-AEA5-8CCBA92E1003 Q33882297-80F3CDAA-C276-4C0F-BA21-854CA869E012 Q34126362-DF3BF815-9F86-466A-B0C3-F5A29FD6C9C3 Q34206822-24248198-0DD7-49E9-8534-6D0D6AAE3143 Q34230865-5172E082-035F-455F-9AFB-F8DD730A7B1B Q34263826-6F26F049-4111-40C6-B7A7-3E337C89628B Q34448487-0038ACEF-BE9F-4D70-9C5E-EE3C1C968668 Q34522097-4975BC91-F7A0-43C8-B028-B6307AD25B1E Q34685137-C0124748-6079-4123-9E46-C7B2D23DA230 Q34982051-8834DDAD-2FD3-4333-8166-DC19B81CC6CB Q35024234-9D1B1CAD-064E-4679-A976-F749986CA93B Q35332873-105D3A3E-8F74-4162-81C1-9A00265F0614 Q35560054-ED1E80F4-DB76-458D-94F7-58A09E6C324B Q35817938-038AFCDA-2EC1-4742-B9F8-1B13A65FE7BD Q35863828-7A2D775D-CF6A-4127-A29E-ACBE468D5EBB Q35907009-8492552D-2CFF-4E89-B92C-611DD3EAC3DB Q35951840-4233F2B3-D3B5-42B7-ADEF-6B7FD4D9A155 Q36188094-4F66CFE4-D9F4-489B-99EA-383E10B83BCC Q36495510-1D23E85E-EA76-4C45-ADE9-D7AE8CDAE6A8 Q36725063-6860E94B-5312-44DB-A955-74F251314323 Q37011339-D15B3D73-A3F6-4DCE-8DBE-732A78E47039 Q37092941-BEC3797D-0527-45D8-B9C8-C5E4AFACB86D Q37118156-2F570283-05D8-4017-A67C-FB5F50CB477C Q37409822-DF96D507-1A2E-497B-93A3-5F0175C06BF7 Q37466085-8965487F-50E7-43E0-806C-AFEDB59C555B Q37603197-765A6AC8-A1DF-4EFC-A42B-8E7612133680 Q37946729-6E43B3F9-214C-4300-BDFA-B9AF36E7A10F Q38054491-548C518D-DD2B-474F-9EA7-4EEAB38505BA Q38627502-94CD0D3D-F674-414D-997B-70A6E68026B3

P2860

Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

http://www.wikidata.org/entity/Q33437576

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Anti-angiogenesis effect of th ...... pro-resolving lipid mediators.

@ast

Anti-angiogenesis effect of th ...... pro-resolving lipid mediators.

@en

type

label

Anti-angiogenesis effect of th ...... pro-resolving lipid mediators.

@ast

Anti-angiogenesis effect of th ...... pro-resolving lipid mediators.

@en

prefLabel

Anti-angiogenesis effect of th ...... pro-resolving lipid mediators.

@ast

Anti-angiogenesis effect of th ...... pro-resolving lipid mediators.

@en

P1433

Q33437576-D932F8AB-FB60-4E39-AFB5-1297190F84E3

P1476

Q33437576-31AC10B6-270E-43F2-AC0E-775562C01D59

P2093

Q33437576-2753AF5B-A24A-4F1D-AD82-835A08ECE543

Q33437576-3F847DBD-907C-49F9-8D25-5B1E5B64C60A

Q33437576-69A4D6CB-8831-4E5E-8B6E-09FA06543525

Q33437576-7ADF900A-035D-4E2B-9AB2-AE8DB8642329

Q33437576-B5E31DAC-1C0F-4499-A2EC-4006C356275C

Q33437576-C40C7EA3-C86A-4392-8959-999B5DCF8377

Q33437576-E51BCCAD-0581-4B0F-825E-DA84F684D245

Q33437576-EE047332-EBAE-4748-BF8E-37D45879EEE0

P2860

Q33437576-0108324C-CE37-441B-9293-67579E16A02D

Q33437576-111628DC-23A1-4655-97A7-A721051BEAF3

Q33437576-19458697-89EA-4F2C-8E03-934A5CCB383C

Q33437576-1AA406EC-6DDA-4064-B48D-28086FCF6691

Q33437576-1E4DA264-A9F7-4CFB-9B57-69060E539BA7

Q33437576-20602B64-B241-4CE3-A038-8D6D6F5ED958

Q33437576-2AF6BFC1-8D79-407C-9AEB-F15789636306

Q33437576-2B8E6D4A-C16A-4A8F-A565-E870BE71FAD4

Q33437576-36D9B4D6-F7B8-4E13-8E56-C751CF464700

Q33437576-3A466E72-0C28-45E3-89F8-AD3BEFBD99D9

P304

Q33437576-7ABFF7E7-2AE3-4914-B1C8-CE039E74E141

P31

Q33437576-42B9A3A9-3C77-4EC4-8414-188AEC9F964D

P356

Q33437576-93D42042-DB21-4F30-8946-BABCBF6A9D5E

P407

Q33437576-4D4B6D13-8D24-4F60-A722-BA718F5CC773

P433

Q33437576-CE4FC309-A81F-49B8-8B1B-E016BDD8A4E0

P478

Q33437576-F95C1D14-8C23-4ED8-9571-98DAF8F235A0

P577

Q33437576-AC45AB7E-81E9-4A46-9055-E5AD87F4416E

P5875

Q33437576-27734317-27D3-447F-AD3B-F7012C9A968F

P698

Q33437576-840FF59F-FC2F-4F65-80E9-D9F15B0FE959

P932

Q33437576-DA78F71B-0D1E-4DE1-B0CA-33DC34A76A97

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

Anti-angiogenesis effect of th ...... pro-resolving lipid mediators.

@en

P2093

Charles N Serhan

http://www.w3.org/2001/XMLSchema#string

Daniel R Saban

http://www.w3.org/2001/XMLSchema#string

Makoto Arita

http://www.w3.org/2001/XMLSchema#string

Nan Chiang

http://www.w3.org/2001/XMLSchema#string

Qiang Zhang

http://www.w3.org/2001/XMLSchema#string

Reza Dana

http://www.w3.org/2001/XMLSchema#string

Sunil K Chauhan

http://www.w3.org/2001/XMLSchema#string

Yiping Jin

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis

Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids

Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release

Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals

International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors

Angiogenesis and lipoxins

Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly

The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo

P304

4743-4752

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.08-2462

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24394033

http://www.w3.org/2001/XMLSchema#string

P698

19407006

http://www.w3.org/2001/XMLSchema#string

P932

2763387

http://www.w3.org/2001/XMLSchema#string